Next Generation Diabetes Therapy and Drug Delivery Market - Global Opportunity Analysis and Industry Forecast, 2014-2023

Friday, May 12, 2017 Drug News
Email Print This Page Comment
Font : A-A+

Next Generation Diabetes Therapy and Drug Delivery Market by Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, and Artificial Pancreas), Demographic [Adult Population (>14 years) & Child Population (<14 years)], Indication (Type 1 Diabetes & Type 2 Diabetes), and End Users (Diagnostics/Clinics, ICUs, and Home Healthcare) - Global Opportunity Analysis and Industry Forecast, 2014-2023>

NEW YORK, May 11, 2017 /PRNewswire/ -- Read the full report: http://www.reportlinker.com/p04883717/Next-Generation-Diabetes-Therapy-and-Drug-Delivery-Market-Global-Opportunity-Analysis-and-Industry-Forecast.htmlNext generation diabetic therapy and drug delivery systems are used to improve the adherence to insulin in diabetic patients to reduce the risk of complications related to sudden change in the blood sugar level.

Oral & inhalable insulin painlessly manage the blood glucose level, and is expected to replace the injectable insulins. The use of advanced diabetic systems, such as insulin patches, CGM systems, and artificial pancreas is expected to maintain adherence to medication in diabetic patients and improve the quality of life of diabetic patients. The global next generation diabetes therapy and drug delivery market was valued at $617 million in 2015, and is estimated to reach $9,673 million by 2023, registering a CAGR of 41.1% from 2016 to 2023. The global next generation diabetes therapy and drug delivery market is segmented based on product type, demographic, indication, end user, and geography. Based on product type, it is classified into inhalable insulin, oral insulin, insulin patches, continuous glucose monitoring (CGM) systems, and artificial pancreas. Based on demographics, it is bifurcated into adult population (>14 years) and child population (?14 years). Based on indication, it is divided into type 1 diabetes and type 2 diabetes. Based on end users, it is categorized into diagnostic/clinic, ICU, and home healthcare. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA. The market growth is attributed to the rise in the number of diabetic patients globally and the increase in disposable income among these patients. The benefits of using these advanced devices over conventional products, such as painless mode of insulin delivery and improvement in adherence to medication, and rise in the healthcare expenditure are expected to increase the demand for these products, thus fueling the market growth. However, lack of awareness, cost restrains in the developing regions, and less variability in products are expected to hamper the growth. KEY MARKET BENEFITS This report offers a detailed quantitative analysis of the current market trends from 2014 to 2023 to identify the prevailing opportunities. The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry. The global market is comprehensively analyzed with respect to product type, demographic, indication, end user, and geography. In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning. The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market. KEY PLAYERS PROFILED Johnson & Johnson Abbott Laboratories Medtronic, Inc. Sanofi Novo Nordisk MannKind Corporation Enteris BioPharma Dexcom, Inc. Senseonics Holding, Inc. Medtech KEY MARKET SEGMENTS By Product Type Inhalable Insulin Oral Insulin Insulin Patches CGM Systems Artificial Pancreas By Demographic Adult Population (>14years) Child Population (?14years) By Indication Type 1 Diabetes Type 2 Diabetes By End User Diagnostics/Clinics ICUs Home Healthcare By Geography North America U.S. Canada Mexico Europe Germany UK France Spain Italy Rest of Europe Asia-Pacific Japan China Australia India South Korea Rest of Asia-Pacific LAMEA Brazil Republic of South Africa Saudi Arabia Read the full report: http://www.reportlinker.com/p04883717/Next-Generation-Diabetes-Therapy-and-Drug-Delivery-Market-Global-Opportunity-Analysis-and-Industry-Forecast.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com __________________________Contact Clare: clare@reportlinker.com US: (339)-368-6001Intl: +1 339-368-6001

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/next-generation-diabetes-therapy-and-drug-delivery-market---global-opportunity-analysis-and-industry-forecast-2014-2023-300456376.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook